Search

everythinglearnresearchcommunity

for

Search:↓

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.